Georgina S. Bowyer

Oxford, ENG OX37DQ, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 36 publications

Phase I/IIa study to assess the safety, immunogenicity and efficacy of ChAdOx1-MVA vectored vaccines expressing a novel liver-stage malaria dual antigen LS2 by sporozoite challenge in malaria-naïve adults.

Phase I/IIa study to assess the safety, immunogenicity and efficacy of ChAdOx1-MVA vectored vaccines expressing a novel liver-stage malaria dual antigen LS2 by sporozoite challenge in malaria-naïve adults.

Journal: Wellcome open research

Published: March 19, 2026

Characterisation of human in vitro tumour-associated macrophage models to define translational relevance.

Characterisation of human in vitro tumour-associated macrophage models to define translational relevance.

Journal: Scientific reports

Published: May 01, 2025

LILRB2 blockade facilitates macrophage repolarization and enhances T cell-mediated antitumor immunity.

LILRB2 blockade facilitates macrophage repolarization and enhances T cell-mediated antitumor immunity.

Journal: Journal for immunotherapy of cancer

Published: March 16, 2025

Repertoire, function, and structure of serological antibodies induced by the R21/Matrix-M malaria vaccine.

Repertoire, function, and structure of serological antibodies induced by the R21/Matrix-M malaria vaccine.

Journal: The Journal of experimental medicine

Published: October 14, 2024

R21 in Matrix-M adjuvant in UK malaria-naive adult men and non-pregnant women aged 18-45 years: an open-label, partially blinded, phase 1-2a controlled human malaria infection study.

R21 in Matrix-M adjuvant in UK malaria-naive adult men and non-pregnant women aged 18-45 years: an open-label, partially blinded, phase 1-2a controlled human malaria infection study.

Journal: The Lancet. Microbe

Published: October 05, 2023

Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trials.

Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trials.

Journal: The Lancet. Microbe

Published: October 05, 2023

Temporal profiling of human lymphoid tissues reveals coordinated defense against viral challenge.

Temporal profiling of human lymphoid tissues reveals coordinated defense against viral challenge.

Journal: Nature immunology

Published: February 14, 2023

Obesity Is Associated with Attenuated Tissue Immunity in COVID-19.

Obesity Is Associated with Attenuated Tissue Immunity in COVID-19.

Journal: American journal of respiratory and critical care medicine

Published: September 12, 2022

Mapping single-cell transcriptomes in the intra-tumoral and associated territories of kidney cancer.

Mapping single-cell transcriptomes in the intra-tumoral and associated territories of kidney cancer.

Journal: Cancer cell

Published: May 20, 2022

Tissue Immunity in the Bladder.

Tissue Immunity in the Bladder.

Journal: Annual review of immunology

Published: April 26, 2022

CMV-associated T cell and NK cell terminal differentiation does not affect immunogenicity of ChAdOx1 vaccination.

CMV-associated T cell and NK cell terminal differentiation does not affect immunogenicity of ChAdOx1 vaccination.

Journal: JCI insight

Published: August 17, 2021

Group 3 innate lymphocytes make a distinct contribution to type 17 immunity in bladder defence.

Group 3 innate lymphocytes make a distinct contribution to type 17 immunity in bladder defence.

Journal: iScience

Published: May 25, 2021

Showing 1-12 of 36

Last Updated: 09/26/2026